Los Angeles Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Los Angeles Capital Management’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-85,913	Closed	-$3.46M	–	2334
2026 Q1	$3.46M	Sell	85,913 -865,803	-91%	-$18.7M	0.01%	393
2025 Q4	$19.7M	Buy	951,716 +330,926	+53%	+$7.76M	0.07%	174
2025 Q3	$14M	Buy	+620,790	New	+$14.5M	0.05%	235
2023 Q3	–	Sell	-3,701	Closed	-$337K	–	1114
2023 Q2	$337K	Buy	+3,701	New	+$319K	﹤0.01%	962
2022 Q4	–	Sell	-4,314	Closed	-$295K	–	1185
2022 Q3	$295K	Buy	+4,314	New	+$255K	﹤0.01%	1073
2021 Q2	–	Sell	-13,611	Closed	-$584K	–	1528
2021 Q1	$584K	Buy	13,611 +4,806	+55%	+$227K	﹤0.01%	1149
2020 Q4	$504K	Buy	8,805 +365	+4%	+$15.4K	﹤0.01%	1204
2020 Q3	$255K	Buy	+8,440	New	+$252K	﹤0.01%	1317

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Los Angeles Capital Management's APLS Position: Q2 2026 in Review

Los Angeles Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 85,913 shares — an estimated $3.46M sold.

Los Angeles Capital Management first reported a position in APLS in Q3 2020 and held it in 8 quarters. The position peaked at $19.7M in Q4 2025. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Los Angeles Capital Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Los Angeles Capital Management sold 85,913 Apellis Pharmaceuticals shares in Q2 2026, an estimated $3.46M.
Los Angeles Capital Management first reported a position in Apellis Pharmaceuticals in Q3 2020 and held it in 8 quarters.
Los Angeles Capital Management's Apellis Pharmaceuticals position peaked at $19.7M in Q4 2025.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.